These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Impermeability to quinolones in gram-positive and gram-negative bacteria. Bryan LE; Bedard J Eur J Clin Microbiol Infect Dis; 1991 Apr; 10(4):232-9. PubMed ID: 1864283 [TBL] [Abstract][Full Text] [Related]
3. Mechanisms of quinolone resistance in clinical isolates: accumulation of sparfloxacin and of fluoroquinolones of various hydrophobicity, and analysis of membrane composition. Denis A; Moreau NJ J Antimicrob Chemother; 1993 Sep; 32(3):379-92. PubMed ID: 8262860 [TBL] [Abstract][Full Text] [Related]
6. Ciprofloxacin affects conformational equilibria of DNA gyrase A in the presence of magnesium ions. Sissi C; Perdonà E; Domenici E; Feriani A; Howells AJ; Maxwell A; Palumbo M J Mol Biol; 2001 Aug; 311(1):195-203. PubMed ID: 11469868 [TBL] [Abstract][Full Text] [Related]
7. Quinolone uptake by bacteria and bacterial killing. Diver JM Rev Infect Dis; 1989; 11 Suppl 5():S941-6. PubMed ID: 2549609 [TBL] [Abstract][Full Text] [Related]
8. Effects of divalent cations and functionally related substances on the yeast to mycelium transition in Sporothrix schenckii. Alsina A; Rodríguez-Del Valle N Sabouraudia; 1984; 22(1):1-5. PubMed ID: 6422568 [TBL] [Abstract][Full Text] [Related]
9. Bacterial resistance to the quinolone antimicrobial agents. Hooper DC; Wolfson JS Am J Med; 1989 Dec; 87(6C):17S-23S. PubMed ID: 2690616 [TBL] [Abstract][Full Text] [Related]
10. Comparison of the mechanism of action and resistance of two new fluoroquinolones, rufloxacin and MF961 with those of ofloxacin and fleroxacin in gram-negative and gram-positive bacteria. Piddock LJ; Panchal S; Norte V J Antimicrob Chemother; 1993 Jun; 31(6):855-63. PubMed ID: 8395493 [TBL] [Abstract][Full Text] [Related]
11. Quinolone mode of action. Hooper DC Drugs; 1995; 49 Suppl 2():10-5. PubMed ID: 8549276 [TBL] [Abstract][Full Text] [Related]
12. [The history of the development and changes of quinolone antibacterial agents]. Takahashi H; Hayakawa I; Akimoto T Yakushigaku Zasshi; 2003; 38(2):161-79. PubMed ID: 15143768 [TBL] [Abstract][Full Text] [Related]
13. Comparative study on antagonistic effects of low pH and cation supplementation on in-vitro activity of quinolones and aminoglycosides against Pseudomonas aeruginosa. Blaser J; Lüthy R J Antimicrob Chemother; 1988 Jul; 22(1):15-22. PubMed ID: 3139613 [TBL] [Abstract][Full Text] [Related]
14. Quinolone-cation interactions: a review. Lomaestro BM; Bailie GR DICP; 1991 Nov; 25(11):1249-58. PubMed ID: 1763542 [TBL] [Abstract][Full Text] [Related]
15. Quinolone antimicrobial agents: mechanism of action and resistance development. Bryan LE; Bedard J; Wong S; Chamberland S Clin Invest Med; 1989 Feb; 12(1):14-9. PubMed ID: 2537696 [TBL] [Abstract][Full Text] [Related]
17. [Mechanisms for the development of quinolone resistance]. Kojima M Nihon Rinsho; 1997 May; 55(5):1252-60. PubMed ID: 9155183 [TBL] [Abstract][Full Text] [Related]
18. Effects of divalent metal cations in the growth medium upon sensitivity of batch-grown Pseudomonas aeruginosa to EDTA or polymyxin B. Boggis W; Kenward MA; Brown MR J Appl Bacteriol; 1979 Dec; 47(3):477-88. PubMed ID: 44290 [No Abstract] [Full Text] [Related]
19. Conditions affecting the results of susceptibility testing for the quinolone compounds. Smith SM; Eng RH; Cherubin CE Chemotherapy; 1988; 34(4):308-14. PubMed ID: 3208548 [TBL] [Abstract][Full Text] [Related]
20. The influence of divalent cations on the stability of human rotavirus. Shirley JA; Beards GM; Thouless ME; Flewett TH Arch Virol; 1981; 67(1):1-9. PubMed ID: 6263223 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]